Librela trial
The active substance in Librela is a monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF). Once attached, it prevents NGF from attaching to its receptors (targets) on nerve cells and interrupts the transmission of pain signals. This helps to bring relief from pain. This substance is injected subcutaneously (under their skin) once a month. The purpose of this study is to monitor efficacy of system absorption and monitor joint changes.
condition(s)
osteoarthritis
eligibility information
To participate in the trial, dogs must:
- Have CT-confirmed osteoarthritis in 1 or more limbs
- Be otherwise systemically healthy
- Have concomitant disease well controlled prior to enrollment
- Be amenable to objective gait analysis
- Be able to undergo sedation safely and wear a monitoring collar
This study will take about 1 year, and participants should be able to attend at least 12 in-person appointments.
contact information
If you’re interested in enrolling in this trial, please email [email protected].
Orthopedic Medicine and Mobility Clinical Trials